Named in honor of Joe Fiandra, an Army veteran and constituent of Pennsylvania’s First District who passed away in 2022 following a courageous battle with amyloidosis, the law corrects a long-standing gap in Medicare coverage that prevented many patients from receiving medically necessary infusion therapy at home. Drawing directly from Joe’s experience navigating barriers to care, the Joe Fiandra Access to Home Infusion Act expands Medicare coverage by ensuring that external infusion pumps and certain non-self-administered drugs are covered as Durable Medical Equipment (DME), removing unnecessary obstacles to home-based treatment. The change will benefit seniors nationwide who rely on infusion therapy to manage complex and life-threatening conditions.

“Joe faced his illness with the same courage that defined his life, but the barriers he encountered made an already difficult battle even harder. With this bill becoming law, no family will have to endure those same struggles—and that brings us peace, and profound pride in Joe’s legacy. I am deeply grateful to Congressman Fitzpatrick for standing with us from the beginning, listening to our story, and turning it into action. Having this legislation bear Joe’s name is an honor. It means his fight will spare other families from suffering, and his life will continue to make a difference for years to come,” said Helen Fiandra, wife of Joe Fiandra, Warrington resident.

“Joe Fiandra served our nation with honor, loved his family fiercely, and faced his illness with courage,” said Fitzpatrick. “But his fight revealed a health care system that made an already difficult moment even harder. When I met with Joe’s wife, Helen, she asked for one thing—that no other family would have to endure the same struggle. Now, with the signing of this bill, that promise has become law. Joe Fiandra’s legacy will permanently strengthen how Medicare delivers care—putting patients first and removing barriers that never should have existed. I am grateful to Helen for her strength, her partnership, and her advocacy, and will continue working to ensure our health care system does what it exists to do—help people when they need it most.”

In 2020, the Centers for Medicare and Medicaid Services acknowledged a critical flaw in Medicare policy—proposing to clarify that the Home Infusion Therapy benefit created under the 21st Century Cures Act should cover infusion drugs requiring professional supervision, not just those that are self-administered. That clarification was never finalized, leaving patients without coverage for medically necessary treatments and forcing families to navigate an illogical gap in the system.

The Joe Fiandra Access to Home Infusion Act permanently resolves that gap. By amending the Social Security Act, the law explicitly ensures that external infusion pumps and associated infusion drugs are covered as Durable Medical Equipment (DME) when medically necessary—bringing Medicare policy in line with modern standards of care and real-world patient needs.

Under the law, Medicare coverage applies when:

1. FDA-approved prescribing information requires administration by, or under the supervision of, a health care professional;
2. The drug is administered in the home by a qualified supplier; and
3. The therapy requires frequent administration or infusion rates that necessitate the use of an external pump.

The legislation also strengthens transparency by requiring the Department of Health and Human Services to notify patients of applicable cost-sharing obligations for home infusion therapy compared to other care settings.

Read the full bill text here.

The Joe Fiandra Access to Home Infusion Act is supported by the Amyloidosis Support Group and reflects a broad consensus that Medicare should support care that is clinically appropriate, cost-effective, and centered on patients.

Background:

Congressman Fitzpatrick introduced the Joe Fiandra Access to Home Infusion Act in August 2025 alongside bipartisan partners Neal Dunn, M.D. (FL-02), and Darren Soto (FL-09). The legislation builds on work first advanced in the 118th Congress and reflects sustained bipartisan efforts to close gaps in Medicare coverage for home infusion therapy.

###